Serial plasma osteopontin levels have prognostic value in metastatic breast cancer

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3337-3343

  Bramwell, Vivien H C ^a   Doig, Gordon S ^d,e   Tuck, Alan B ^f,g   Wilson, Sylvia M ^b   Tonkin, Katia S ^c   Tomiak, Anna ^h   Perera, Francisco ^f,g   Vandenberg, Theodore A ^f,g   Chambers, Ann F ^f,g  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f LONDON REGIONAL CANCER PROGRAM   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; OCTREOTIDE; OSTEOPONTIN; PLACEBO; PROGESTERONE; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MARROW METASTASIS; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SKIN METASTASIS; THORAX WALL CANCER; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745187759     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2354     Document Type: Article

References (47)

1. National Cancer Institute of Canada. Canadian cancer statistics 2005. [cited; http://www.cancer.ca/stats/].
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Winer EP, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1651-717.
4. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-53.
5. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
6. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998;52:239-59.
7. Duffy MJ. Evidence for the clinical use of tumour markers. Ann Clin Biochem 2004;41:370-7.
8. Seregni E, Coli A, Mazzucca N. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:515-22.
9. Bast RC, Jr., Lilja H, Urban N, et al. Translational crossroads for biomarkers. Clin Cancer Res 2005;11: 6103-8.
10. Muller V, Pantel K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res 2004;6:258-61.
11. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23:1420-30.
12. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
13. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1998;16:793-5.
14. Bast RC, Jr., Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
15. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997;17:1-15
16. Rittling SR, Denhardt DT. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 1999;7:103-13.
17. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81.
18. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
19. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001;1:621-32.
20. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001;6:419-29.
21. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003; 112:147-9.
22. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988;48:5770-4.
23. Bautista DS, Saad Z, Chambers AF, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996;29:231-9.
24. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-23.
25. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
26. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-8.
27. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184-90.
28. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
29. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-11.
30. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002;95: 506-12.
31. Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. Br J Urol Int 2005;96:803-5.
32. Katz MH, Hauck WW. Proportional hazards (Cox) regression. J Gen Intern Med 1993;8:702-11.
33. Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981; 37:67-78.
34. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-57.
35. Altman DG, De Stavola BL. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994;13:301-41.
36. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979;16:885-93.
37. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-23.
38. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002;62:3417-27.
39. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995;146: 95-100.
40. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
41. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
42. Saeki Y, Mima T, Ishii T, et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 2003;123: 263-70.
43. Le QT Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003;9:59-67.
44. Ali SM, Leitzel K, Chinchilli VM, et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002;48: 1314-20.
45. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967-72.
46. Hayes DF. Designing tumor marker studies: will the results provide clinically useful information Arch Pathol Lab Med 2000;124:952-4.
47. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88: 1456-66.